Compare · HEPA vs LLY
HEPA vs LLY
Side-by-side comparison of Hepion Pharmaceuticals Inc. (HEPA) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HEPA and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY carries a market cap of $1.36T.
- LLY has been more active in the news (30 items in the past 4 weeks vs 9 for HEPA).
- LLY has more recent analyst coverage (25 ratings vs 1 for HEPA).
- Company
- Hepion Pharmaceuticals Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- -
- $1.36T
- 1M return
- -
- +15.42%
- 1Y return
- -
- +41.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 9
- 30
- Recent ratings
- 1
- 25
Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing CRV431, a cyclophilin inhibitor that is in Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest HEPA
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- SEC Form 4 filed by Hepion Pharmaceuticals Inc.
- Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest
- Amendment: SEC Form SCHEDULE 13G/A filed by Hepion Pharmaceuticals Inc.
Latest LLY
- Lilly to present new data across Zepbound, Foundayo, EloraTZP and retatrutide at ObesityWeek 2026, moving obesity care beyond the scale
- Weekly Gains Hold Up Despite a Friday Slide as Chips Lead and Yields Climb
- Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
- Nasdaq Jumps Over 4% This Week as Chip Names Drive a Sharp Midweek Rally
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
- EVP & President, LLY Int'l Jonsson Patrik gifted 704 shares, decreasing direct ownership by 1% to 53,443 units (SEC Form 4)
- Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
- Indices Hunt for Support After Steep Weekly Losses as Volatility Gauge Stays Elevated
- Lilly's Foundayo (orforglipron) significantly reduced obstructive sleep apnea severity, reinforcing its potential to improve health beyond weight loss
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium